Grünwald Viktor, Heinzer Hans, Fiedler Walter
Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Germany.
Onkologie. 2007 Oct;30(10):519-24. doi: 10.1159/000107721. Epub 2007 Sep 21.
Anti-angiogenetic agents are currently considered standard therapy for metastatic renal cell carcinoma (RCC) for the majority of the patients. In contrast to immuno- or chemotherapy, the inhibition of specific signaling pathways has been considered essentially non-toxic. The advance of these tyrosine kinase inhibitors into clinical practice has led to a more detailed understanding of their targets in both, the tumor and the patient. At the advent of targeted therapies, oncologists are in the process of developing surveillance strategies tailored for specific side effects of individual classes of agents to the individual needs of patients. In the current article, the significance of adverse events and their management in RCC patients is reviewed in order to guide the clinical oncologist through patient surveillance and treatment of adverse events.
目前，抗血管生成药物被认为是大多数转移性肾细胞癌（RCC）患者的标准治疗方法。与免疫疗法或化疗不同，抑制特定信号通路基本上被认为是无毒的。这些酪氨酸激酶抑制剂在临床实践中的应用使人们对其在肿瘤和患者体内的靶点有了更深入的了解。在靶向治疗出现之际，肿瘤学家正在制定监测策略，以根据各类药物的特定副作用和患者的个体需求进行量身定制。在本文中，我们回顾了RCC患者不良事件的重要性及其管理，以指导临床肿瘤学家对患者进行监测和不良事件的治疗。
